Forget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner

2026-03-11 14:50:00 ET

In January, Novo Nordisk (NYSE: NVO) broke new ground in the weight-loss market by launching an oral version of its famous anti-obesity drug, Wegovy. It's the first oral GLP-1 approved for chronic weight management, and Novo Nordisk hopes it will help it regain market share in this area.

While oral Wegovy has so far had a successful launch, another oral GLP-1 could hit the market this year and eclipse it. Here's what investors need to know.

Image source: Getty Images.

Continue reading